GlassScriptPhysician profile
Weimin Qu
NPI 1831169473
$3,203.64
in general payments reported to CMS, 2019-2025
16 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $177 · 2021: $831 · 2022: $350 · 2023: $417 · 2024: $267 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,326.75 | 2019-2023 | |
| Pfizer INC. | $362.51 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $340.11 | 2023-2025 | Myfembree |
| Agile Therapeutics, INC. | $235.37 | 2021-2024 | Twirla |
| Millicent US INC | $162.66 | 2019-2024 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $137.24 | 2019-2020 | |
| Lupin INC. | $121.24 | 2019 | |
| Amgen INC. | $118.73 | 2019 | |
| Mayne Pharma Commercial LLC | $118.03 | 2024 | |
| Astellas Pharma US INC | $71.22 | 2023-2024 | Veozah |
| Mylan Pharmaceuticals INC. | $60.82 | 2019 | |
| Myovant Sciences INC. | $46.79 | 2021-2022 | |
| Exeltis, USA INC. | $43.42 | 2025 | Slynd |
| Coopersurgical, INC. | $22.86 | 2023 | Paragard T 380a |
| Hologic Sales and Service, LLC | $20.84 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $15.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weimin Qu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.